TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has issued an update.
Zhaoke Ophthalmology Ltd. has entered into a distribution agreement with PT Ferron Par Pharmaceuticals to commercialize BRIMOCHOL™ PF, an innovative presbyopia treatment, in Indonesia. This strategic move grants PT Ferron exclusive rights to market and sell the drug, potentially strengthening Zhaoke’s presence in the Southeast Asian market and addressing the unmet need for presbyopia treatments in the region.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Ltd. is a company focused on the ophthalmology industry, specializing in innovative treatments for eye conditions. The company is involved in the development and commercialization of ophthalmic drugs, with a market focus on regions where presbyopia affects a significant portion of the population.
Average Trading Volume: 2,046,997
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.72B
Learn more about 6622 stock on TipRanks’ Stock Analysis page.